Wird geladen...
Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy
Sustained therapeutic responses from traditional and next-generation antiandrogen therapies remain elusive in clinical practice due to inherent and/or acquired resistance resulting in persistent androgen receptor (AR) activity. Antisense oligonucleotides (ASO) have the ability to block target gene e...
Gespeichert in:
| Veröffentlicht in: | JCI Insight |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Society for Clinical Investigation
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6777919/ https://ncbi.nlm.nih.gov/pubmed/31484823 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.122688 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|